Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (April 2024)
28 slides from Adherium's investor presentation, Apr 26, 2024
Slide 1: Hailie®
Hailie® One of the leading technically advanced Digital Adherence Monitoring Systems in the World
Slide 2: Disclaimer and forward-looking statement
Disclaimer and forward-looking statement The material contained herein is of a general nature & has only been prepared as a These risks & uncertainties include, but are not limited to: presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adh
Slide 3: Investment Highlights
Advanced product portfolio Investment Global leader in the provision of integrated digital health solutions and connected Highlights respiratory medical device. 12 US FDA (510K)1 cleared inhalation sensors on market Market size Asthma costs the US healthcare system US$82B2 and COPD US$31.3 billion3
Slide 4: Unmet Medical Need
Unmet Medical Need Technology-led drug adherence, measured benefits in respiratory health outcomes
Slide 5: Asthma and Chronic Obstructive Pulmonary Disease (COPD) Patients
Unmet Medical Need Asthma and Chronic Obstructive Pulmonary Disease (COPD) Patients* Asthma $82B1 21M3 American 4.9M11 asthma 939,00011 asthma 94,56012 asthma cost on Healthcare adults have asthma doctor visits/yr ER visits/yr hospitalizations/yr system, COPD $ 31.3B2 and 4.8M4 children: 15.4M9 COPD
Slide 6: Factors contributing to suboptimal adherence in asthma and COPD
Unmet Need Factors contributing to suboptimal adherence in asthma and COPD Medication Unintentional Intentional > Complex regimen > Age-related factors > Perception of > Multiple inhalers > Forgetfulness treatment/illness > Inhaler technique > Misunderstood directions > Denial/anger about disease >
Slide 7: How smart inhaler technology can help people with asthma and COPD
Feb. 27, 2023 / Cleveland Clinic How smart inhaler technology can help people with asthma and COPD1 In one of the first-of-its-kind outcome studies, Cleveland Clinic researchers found that the use of electronic inhaler monitoring, in combination with a disease management program, is associated with
Slide 8: Adherium’s Digital Adherence Monitoring System (ADAMS)
Hailie Adherence device covers 90% of US top 20 Drug agnostic inhaler medications sensors (12 1 Hailie Adherence Devices) Solution Adherium’s Digital Adherence Monitoring System (ADAMS) 1. FDA 510(k) searchable database Confidential ©Adherium 2024 8
Slide 9: What makes Hailie one of the leading technically advanced systems
What makes Hailie® Sensor includes the following us one of the leading technically advanced Inhalation Parameters User Interface Digital Adherence Sensor : Mass Airflow Sensor Sensor : Tactile light touch switch & Tricolor LED Monitoring Systems in the world Medication Inhaler Actuation Installed/ R
Slide 10: Hailie® App
Hailie® App Insights Dashboard Reminders settings Adherence Confidential ©Adherium 2024 10
Slide 11: Patient Triage Dashboard
Hailie® Portal Patient Triage Choose the clinical group Dashboard of interest Choose the time-period of interest Click on the info icons for a description Click on the hotspots to filter patients by medication use or sensor status Automatically sorting of patients in terms of Click on the patient ri
Slide 12: Patient Management Dashboard
Hailie® Portal Patient Click to edit patient details Management Dashboard Timer logs clinical time Notes tab Prescription and to capture sensor status clinical notes Medication use and Adherence inhalation data Calendar Rescue daily totals Confidential ©Adherium 2024 12
Slide 13: US Market Penetration Strategy
US Market Penetration Strategy Experienced team, primed for growth
Slide 14: Improving health outcomes and quality of life for patients
Improving health outcomes and quality of life for patients
Slide 15: Phase 1: Where we were
Targeted channels in stages Phase 1: Where we were Clinical trials > Pharmaceutical industry > Clinical Research Organizations Development of the adherence sensor systems for Pharmaceutical Company’s Clinical Trials Confidential ©Adherium 2024 15
Slide 16: Phase 2: Where we are
Targeted channels in stages Phase 2: Where we are Allergy Partners1 > Largest US allergy & asthma practice based in North Carolina > Over 300,000 asthma patients across 140 sites in 20 states > First patients3 onboarded Sep’23 > Hailie platform deployed to enable scaling Medical groups Hospital Syst
Slide 17: Hear from our customers and patients
Hear from our customers and patients Patient testimonial Our 8-year-old daughter had two exacerbations in the year before we started using Hailie. We’ve been using Hailie for nearly a year and a half now, and we haven’t had any exacerbations. John G. Dr. Bill McCann Allergy Partners Chief Medical Of
Slide 18: Hailie® Partnerships
Partners already using Hailie Hailie® Partnerships 1 7 2 8 9 3 9 7 4 10 8 4 3 6 11 5 8 3 5 6 1 6 4 1 5 Current discussions with prospective 10 partners include 2 10 1 6 2 2 7 7 9 3 8 4 9 5 Source: ADR management Confidential ©Adherium 2024 18
Slide 19: Hailie Platform enables RPM and RTM CMS reimbursement code sets
Adherium’s Hailie® Platform enables utilisation of RPM and RTM CMS reimbursement code sets For Illustrative Purposes Only for Eligible Patients One-time initial set-up Device supply and data Clinical staff review Clinical staff review and patient education transmitted from device (20min; billable mo
Slide 20: “One Button” Model
“One Button” Doc requests Logistics partnerships Hailie® from EMR specified Hailie to Model patient’s home Notification of successful delivery ADR gets ADR Set up Call patient notification > Check insurance patient on to on-board > Determine device Hailie Portal > Trigger logistics to ship to patien
Slide 21: Phase 3: Where we are going
Targeted channels in stages: what’s in it for me? Phase 3: Where we are going Pharmacy benefit Healthcare Value-based payment managers (pbms) payers5 incentives > CareMark Government payers > Asthma $82b1 cost on healthcare system > Express Scripts Private health insurance > 21m2 American adults hav
Slide 22: Highly Credentialled Team
Highly Credentialled Team Primed for growth
Slide 23: Adherium Global Locations
Adherium UK Hospital and Global Locations Clinical Trials Manufacturing Lamphun Thailand Business Growth and US HQs R&D Auckland New Zealand HQs Melbourne Australia Confidential ©Adherium 2024 23
Slide 24: New CEO
New CEO It is a combination of incredibly motivating factors of ‘right time, right market conditions, right knowledge, right network’ that have motivated me to join the Adherium team – as it is here, in the company of dedicated professionals with world-leading technology at our fingertips, that I ca
Slide 25: Highly experienced leadership team
Highly experienced leadership team Dr. Paul Mastoridis Francis White Daniel Kaplon Chris Leigh-Lancaster Tara Creaven-Capasso Cassandra Thomas Chief Executive Officer Vice President, Global Business Chief Financial Officer VP, Product & Technology Vice President, Quality, Vice President, People & Cu
Slide 26: Highly experienced leadership team
Highly experienced leadership team John Giszczak Luke Allera Nigel Devine Nancy She Zoe Park Santhosh Varghese Director, Business Development Director, Strategy and Sales Vice President Production Head of Supply Chain/ Head of Software IT Systems Manager Operations & Development Procurement > 18 yea
Slide 27: Corporate Snapshot
Corporate Snapshot Capital Structure1 Experienced and Proven Board2 Share Price $0.029 Member Description Shares on Issue 340.0m Mr.Panaccio has extensive experience in the life sciences sector at the Lou Panaccio executive and board level. He is currently a director at Avita Cash $3.14m Independent
Slide 28: Thank you
Thank you